Evaluating AAA617 alone and with ARPI for advanced prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and effectiveness of AAA617, a targeted therapy, both alone and in combination with androgen receptor pathway inhibitors (ARPI), in patients with prostate cancer that is positive for PSMA and resistant to castration. Approximately 120 participants will be randomized to receive either treatment, focusing on those who show no signs of metastasis in conventional imaging. The study will utilize advanced imaging techniques to confirm the presence of PSMA-positive disease and monitor treatment outcomes.

Why it matters

Who can join: the full rules

Key Inclusion criteria

* Participants must be adults ≥ 18 years of age with signed informed consent prior to participation to study
* Histologically or cytologically confirmed prostate cancer
* Participants must have ongoing androgen deprivation therapy with a GnRH agonist/antagonist or prior bilateral orchiectomy
* Castrate level of serum testosterone (\< 1.7 nmol/l \[50 ng/dl\]) on GnRH agonist or antagonist therapy or after bilateral orchiectomy
* Participants must have evidence of PSMA-positive disease as seen on a AAA517 or piflufolastat F 18 PET/CT scan at baseline as determined by Blinded Independent Central Review (BICR) based on the methodology proposed in the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) (Eiber et al 2018). Participants with M1 disease only on PSMA PET scan are allowed to participate
* Participants must have a negative conventional imaging for M1 disease.
* PSA Doubling Time (PSADT) of ≤ 10 months
* Participants must have adequate organ functions: bone marrow reserve, hepatic \& renal

Key Exclusion criteria

* Prior or present evidence of metastatic disease as assessed by CT/MRI locally for soft tissue disease and whole-body radionuclide bone scan for bone disease. Exception: Participants with soft tissue pelvic disease may be eligible (e.g., participants with enlarged lymph nodes below the aortic bifurcation (N1) are eligible if the short axis of the largest lymph node is \<20 mm)
* Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable with best available standard of care (incl. pads, drainage) are allowed
* Active clinically significant cardiac disease; history of seizure or condition that may pre-dispose to seizure which may require treatment with surgery or radiation therapy
* Prior therapy with: second generation anti-androgens (e.g., enzalutamide, apalutamide and darolutamide); CYP17 inhibitors (e.g., abiraterone acetate, orteronel, galeterone, ketoconazole; radiopharmaceutical agents (e.g., Strontium-89), PSMA-targeted radioligand therapy; immunotherapy (e.g., sipuleucel-T); chemotherapy, except if administered in the adjuvant/neoadjuvant setting, completed \> 2 years before randomization; any other investigational agents for CRPC; use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) or first-generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) within 28 days before randomization; radiation therapy (external beam radiation therapy \[EBRT\] and brachytherapy within 28 days before randomization
* Other concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, biological therapy or investigational therapy

Other protocol-defined inclusion/exclusion criteria may apply.

Where it's running

• Urology Associates of Mobile
  Mobile, Alabama, United States Recruiting
• Rocky Mountain Cancer Centers
  Longmont, Colorado, United States Recruiting
• University Cancer and Blood Center LLC
  Athens, Georgia, United States Recruiting
• Unity Point Clinic
  Des Moines, Iowa, United States Recruiting
• Urology Cancer Center PC
  Omaha, Nebraska, United States Recruiting
• Associated Med Professionals of NY
  Syracuse, New York, United States Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: 1-888-669-6682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using AI to help find prostate cancer on MRI

  This study tests whether an AI software can help doctors find suspicious lesions on prostate MRI in men aged 55–80 who are having a pre-biopsy MRI and planned prostate biopsy.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07084779

• Understanding how obesity-related factors influence prostate cancer progression

  This study looks at how being overweight or obese affects prostate cancer by checking certain enzymes and immune cells in tumor samples from patients with different body weights.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT06292897

• Evaluating Ifosfamide/Mesna for Advanced Prostate Cancer

  This study is testing whether a combination of ifosfamide and mesna can help people with advanced prostate cancer who haven't had success with other treatments.

  Recruiting Yonsei University · Seoul · NCT06236789

• Using augmented reality to improve prostate cancer surgery outcomes

  This study is testing whether using augmented reality during prostate cancer surgery can lead to better outcomes and help preserve erectile function compared to standard surgery methods.

  Recruiting European Institute of Oncology · Milan · NCT06059859

• Understanding factors affecting prostate cancer progression

  This study is trying to find out what factors affect how prostate cancer grows in different people to help improve treatment and prevention for those at higher risk.

  Recruiting Centre Hospitalier Universitaire de la Guadeloupe · Rennes, Ille-et-Vilaine and 1 other locations · NCT06046131

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.